Hormones appear to play an important protective role in colorectal cancer (CRC) in women. The use of exogenous estrogens has been consistently associated with a roughly 40% decrease in risk of CRC, and higher levels of circulating estrogens, such as those that occur in obese women, also appear to reduce risk. It is not clear, however, whether estrogens affect risk of all types of CRC equally, or whether their effects are associated with distinct molecular characteristics and outcomes of colorectal cancers. For example, emerging evidence suggests that estrogens may be related to the presence of epigenetic changes, particularly CpG island hypermethylation, and that these epigenetic changes may affect survival after a diagnosis of CRC. We propose to extend our recently completed case-control study of postmenopausal hormones and CRC risk (CA 76366) to examine the relationship between estrogen use, the presence of specific molecular tumor characteristics, and CRC outcomes (i.e., new primary CRC and death). We will specifically evaluate: 1) the relationship of pre-diagnosis exposures, such as postmenopausal hormone (PMH) use, with CRC outcomes;2) the relationship of PMH use with the CpG island methylator phenotype (CIMP) status and the hMLH1 promoter methylation status of the colorectal tumors;and 3) the association between molecular features of the original tumor (i.e., CIMP status, hMLH1 promoter methylation, hMLH1 expression) and CRC outcomes. To accomplish these specific aims, we will analyze tumor tissue and questionnaire data from an estimated 900 of the 1,018 women aged 50-74 years with invasive CRC who were identified from the Puget Sound SEER registry and participated in our prior study. We will use follow-up information from the SEER registry to assess the occurrence of new primary CRC and vital status over an average of five years following diagnosis, and methylation will be assessed using MethyLight. This research will provide practical information for women with CRC and their physicians about the possible prognostic importance of PMH use, and it may also lead to a better understanding of the mechanisms through which hormones affect risk of CRC and specific molecular subtypes of CRC in women.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA076366-09
Application #
7680044
Study Section
Epidemiology of Cancer Study Section (EPIC)
Program Officer
Nelson, Stefanie A
Project Start
1998-08-19
Project End
2012-05-31
Budget Start
2009-06-01
Budget End
2012-05-31
Support Year
9
Fiscal Year
2009
Total Cost
$411,804
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Neumeyer, Sonja; Banbury, Barbara L; Arndt, Volker et al. (2018) Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer. Br J Cancer 118:1639-1647
Wang, Xiaoliang; Chan, Andrew T; Slattery, Martha L et al. (2018) Influence of Smoking, Body Mass Index, and Other Factors on the Preventive Effect of Nonsteroidal Anti-Inflammatory Drugs on Colorectal Cancer Risk. Cancer Res 78:4790-4799
Toth, Reka; Scherer, Dominique; Kelemen, Linda E et al. (2017) Genetic Variants in Epigenetic Pathways and Risks of Multiple Cancers in the GAME-ON Consortium. Cancer Epidemiol Biomarkers Prev 26:816-825
Gu, Fangyi; Zhang, Han; Hyland, Paula L et al. (2017) Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia. Int J Cancer 141:1794-1802
Lindström, Sara; Finucane, Hilary; Bulik-Sullivan, Brendan et al. (2017) Quantifying the Genetic Correlation between Multiple Cancer Types. Cancer Epidemiol Biomarkers Prev 26:1427-1435
Zeng, Chenjie; Matsuda, Koichi; Jia, Wei-Hua et al. (2016) Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk. Gastroenterology 150:1633-1645
Garcia-Albeniz, Xabier; Rudolph, Anja; Hutter, Carolyn et al. (2016) CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk. Br J Cancer 114:221-9
Karami, Sara; Han, Younghun; Pande, Mala et al. (2016) Telomere structure and maintenance gene variants and risk of five cancer types. Int J Cancer 139:2655-2670
Hung, Rayjean J; Ulrich, Cornelia M; Goode, Ellen L et al. (2015) Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. J Natl Cancer Inst 107:
Phipps, Amanda I; Limburg, Paul J; Baron, John A et al. (2015) Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 148:77-87.e2

Showing the most recent 10 out of 36 publications